Compass Therapeutics Stock Alpha and Beta Analysis
| CMPX Stock | USD 2.24 0.02 0.88% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Compass Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Compass Therapeutics over a specified time horizon. Remember, high Compass Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Compass Therapeutics' market risk premium analysis include:
Beta 3.09 | Alpha 0.96 | Risk 7.92 | Sharpe Ratio 0.14 | Expected Return 1.11 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Compass |
Compass Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Compass Therapeutics market risk premium is the additional return an investor will receive from holding Compass Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Compass Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Compass Therapeutics' performance over market.| α | 0.96 | β | 3.09 |
Compass Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Compass Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Compass Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Compass Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Compass Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Compass Therapeutics shares will generate the highest return on investment. By understating and applying Compass Therapeutics stock market price indicators, traders can identify Compass Therapeutics position entry and exit signals to maximize returns.
Compass Therapeutics Return and Market Media
The median price of Compass Therapeutics for the period between Fri, Dec 20, 2024 and Thu, Mar 20, 2025 is 2.6 with a coefficient of variation of 29.93. The daily time series for the period is distributed with a sample standard deviation of 0.74, arithmetic mean of 2.47, and mean deviation of 0.63. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 58054 shares by Schuetz Thomas J. of Compass Therapeutics at 1.86 subject to Rule 16b-3 | 01/08/2025 |
2 | Why Compass Therapeutics Inc Is Skyrocketing So Far In 2025 - Yahoo Finance | 02/03/2025 |
3 | Why Compass Therapeutics Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
4 | Disposition of 41687 shares by Schuetz Thomas J. of Compass Therapeutics at 3.5 subject to Rule 16b-3 | 02/07/2025 |
5 | Compass Therapeutics, Inc. Upgraded to Buy What Does It Mean for the Stock | 02/10/2025 |
6 | ADAGE CAPITAL PARTNERS GP, L.L.C. Reduces Stake in Compass Therapeutics Inc | 02/12/2025 |
7 | Acquisition by Shin Barry of 250000 shares of Compass Therapeutics at 3.65 subject to Rule 16b-3 | 02/13/2025 |
8 | Compass Therapeutics Shares Down 7.6 percent - Should You Sell - MarketBeat | 02/14/2025 |
9 | Piper Sandler Begins Coverage on Compass Therapeutics - MarketBeat | 02/20/2025 |
10 | Insider Trading | 02/26/2025 |
11 | Acquisition by Gray Mary Ann of 45000 shares of Compass Therapeutics subject to Rule 16b-3 | 02/28/2025 |
12 | Stifel maintains Compass Therapeutics stock Buy rating, 10 target - Investing.com | 03/10/2025 |
13 | Acquisition by Schuetz Thomas J. of 30000 shares of Compass Therapeutics at 2.83 subject to Rule 16b-3 | 03/11/2025 |
14 | With 42 percent stake, Compass Therapeutics, Inc. seems to have captured institutional investors interest | 03/18/2025 |
About Compass Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Compass or other stocks. Alpha measures the amount that position in Compass Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | |
| Current Ratio | 12.05 | 19.73 | 17.75 | 18.64 |
| Net Debt To EBITDA | 0.86 | 0.46 | 0.42 | 0.4 |
Compass Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Compass Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Compass Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Compass Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Compass Therapeutics. Please utilize our Beneish M Score to check the likelihood of Compass Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Compass Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.